ConductScience.org, home

Paper23908265

Designing the magic bullet? The advancement of immuno-PET into clinical use.

Wright BD and 1 other. J Nucl Med, 2013. Cited by 49 papers, by iCite.

Cite this record

ConductScience Library. Designing the magic bullet? The advancement of immuno-PET into clinical use. Papers, record 23908265. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23908265

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Designing the magic bullet? The advancement of immuno-PET into clinical use.
PubMed
Journal
J Nucl Med
PubMed
Year
2013
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
49
iCite
Relative citation ratio, by iCite
1.71
iCite
Revised in PubMed
2015-11-19
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wright BDBrian D
2Lapi SESuzanne E

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
Positron-Emission TomographyMajor topic
Humans
Iodine Radioisotopes
Isotope Labeling
Zirconium

Cited by33

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 49 citations.

PMIDTitleJournalYearIn PapersSource
42588729Predicting Therapeutic Response to Antibody-Drug Conjugates Using Targeted PET Imaging: A Systematic Review.Cancers (Basel)2026https://conductscience.org/library/papers/42588729PubMed
37991639Optimized, automated and cGMP-compliant synthesis of the HER2 targeting [68Ga]Ga-ABY-025 tracer.EJNMMI Radiopharm Chem2023https://conductscience.org/library/papers/37991639PubMed
36936995Molecular imaging of HER2 receptor: Targeting HER2 for imaging and therapy in nuclear medicine.Front Mol Biosci2023https://conductscience.org/library/papers/36936995PubMed
36559316Engineering of a Fully Human Anti-MUC-16 Antibody and Evaluation as a PET Imaging Agent.Pharmaceutics2022https://conductscience.org/library/papers/36559316PubMed
36145664Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates.Pharmaceutics2022https://conductscience.org/library/papers/36145664PubMed
35563414Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.Int J Mol Sci2022https://conductscience.org/library/papers/35563414PubMed
35314661Validation of In Vivo Nodal Assessment of Solid Malignancies with USPIO-Enhanced MRI: A Workflow Protocol.Methods Protoc2022https://conductscience.org/library/papers/35314661PubMed
34804069Noninvasive Immuno-PET Imaging of CD8+ T Cell Behavior in Influenza A Virus-Infected Mice.Front Immunol2021https://conductscience.org/library/papers/34804069PubMed
33466827Radiochemistry, Production Processes, Labeling Methods, and ImmunoPET Imaging Pharmaceuticals of Iodine-124.Molecules2021https://conductscience.org/library/papers/33466827PubMed
33205364Improved non-invasive positron emission tomographic imaging of chemotherapy-induced tumor cell death using Zirconium-89-labeled APOMAB®.EJNMMI Radiopharm Chem2020https://conductscience.org/library/papers/33205364PubMed
33169605Polyazamacrocycle Ligands Facilitate 89Zr Radiochemistry and Yield 89Zr Complexes with Remarkable Stability.Inorg Chem2020https://conductscience.org/library/papers/33169605PubMed
32048177Identifying Biomarkers in Lymph Node Metastases of Esophageal Adenocarcinoma for Tumor-Targeted Imaging.Mol Diagn Ther2020https://conductscience.org/library/papers/32048177PubMed
31667145An update on PET-based molecular imaging in neuro-oncology: challenges and implementation for a precision medicine approach in cancer care.Quant Imaging Med Surg2019https://conductscience.org/library/papers/31667145PubMed
31095372Multimodal Positron Emission Tomography Imaging to Quantify Uptake of 89Zr-Labeled Liposomes in the Atherosclerotic Vessel Wall.Bioconjug Chem2020https://conductscience.org/library/papers/31095372PubMed
3086549389Zr-DFO-Cetuximab as a Molecular Imaging Agent to Identify Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma.Cancer Biother Radiopharm2019https://conductscience.org/library/papers/30865493PubMed
30755811Antibody and fragment-based PET imaging of CTLA-4+ T-cells in humanized mouse models.Am J Cancer Res2019https://conductscience.org/library/papers/30755811PubMed
30370812Application of Immuno-PET in Antibody-Drug Conjugate Development.Mol Imaging2018https://conductscience.org/library/papers/30370812PubMed
29462554Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics.ACS Nano2018https://conductscience.org/library/papers/29462554PubMed
29450576ImmunoPET imaging of CD38 in murine lymphoma models using 89Zr-labeled daratumumab.Eur J Nucl Med Mol Imaging2018https://conductscience.org/library/papers/29450576PubMed
29363548Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models.Cancer Res2018https://conductscience.org/library/papers/29363548PubMed

See all 33 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/23908265

GET https://conductscience.org/api/papers/v1/23908265/cited_by?page=2